Diabetes, metabolic comorbidities, and risk of hepatocellular carcinoma: Results from two prospective cohort studies

DOI: 10.1002/hep.29660
Hepatology, 2018, 67, 1797-1806.

#	Paper	IF	Citations
85	Diabetes Mellitus and Risk of Hepatocellular Carcinoma. *BioMed Research International*, **2017**, 2017, 5202684	3	29
84	Acyclic retinoid and angiotensin-II receptor blocker exert a combined protective effect against diethylnitrosamine-induced hepatocarcinogenesis in diabetic OLETF rats. *BMC Cancer*, **2018**, 18, 1164	4.8	3
83	Type 2 diabetes and risk of colorectal cancer in two large U.S. prospective cohorts. *British Journal of Cancer*, **2018**, 119, 1436-1442	8.7	34
82	Association Between Aspirin Use and Risk of Hepatocellular Carcinoma. *JAMA Oncology*, **2018**, 4, 1683-1690	9.4	105
81	Diabetes und Gastroenterologie Update 2017. *Diabetologe*, **2018**, 14, 311-318	0.2	1
80	Comorbid chronic diseases and cancer diagnosis: disease-specific effects and underlying mechanisms. *Nature Reviews Clinical Oncology*, **2019**, 16, 746-761	19.4	38
79	Concurrent nonalcoholic fatty liver disease and type 2 diabetes: diagnostic and therapeutic considerations. *Expert Review of Gastroenterology and Hepatology*, **2019**, 13, 849-866	4.2	24
78	Key genes associated with diabetes mellitus and hepatocellular carcinoma. *Pathology Research and Practice*, **2019**, 215, 152510	3.4	14
77	Obesity and Hepatocarcinogenesis. **2019**, 87-102		
76	High glucose regulates ERp29 in hepatocellular carcinoma by LncRNA MEG3-miRNA 483-3p pathway. *Life Sciences*, **2019**, 232, 116602	6.8	12
75	The SGLT2 Inhibitor Canagliflozin Prevents Carcinogenesis in a Mouse Model of Diabetes and Non-Alcoholic Steatohepatitis-Related Hepatocarcinogenesis: Association with SGLT2 Expression in Hepatocellular Carcinoma. *International Journal of Molecular Sciences*, **2019**, 20,	6.3	26
74	Synergistic activation of mitochondrial metabolism and the glutathione redox couple protects HepG2 hepatocarcinoma cells from palmitoylcarnitine-induced stress. *American Journal of Physiology - Cell Physiology*, **2019**, 317, C1324-C1329	5.4	3
73	Diabetes in Liver Disease. **2019**, 65-86		
72	Metabolic syndrome and liver-related events: a systematic review and meta-analysis. *BMC Endocrine Disorders*, **2019**, 19, 40	3.3	22
71	Impact of dapagliflozin, an SGLT2 inhibitor, on serum levels of soluble dipeptidyl peptidase-4 in patients with type 2 diabetes and non-alcoholic fatty liver disease. *International Journal of Clinical Practice*, **2019**, 73, e13335	2.9	39
70	Environmental risk factors for liver cancer and nonalcoholic fatty liver disease. *Current Epidemiology Reports*, **2019**, 6, 50-66	2.9	24
69	Association between diabetes mellitus and hepatocellular carcinoma. *European Journal of Gastroenterology and Hepatology*, **2019**, 31, 898-899	2.2	1

68	Type 2 Diabetes Prevention Diet and Hepatocellular Carcinoma Risk in US Men and Women. *American Journal of Gastroenterology*, **2019**, 114, 1870-1877	0.7	12
67	Association between metabolic syndrome and hepatobiliary cancers: A case-control study. *Indian Journal of Gastroenterology*, **2019**, 38, 61-68	1.9	7
66	Role of MicroRNAs in the Development of Hepatocellular Carcinoma in Nonalcoholic Fatty Liver Disease. *Anatomical Record*, **2019**, 302, 193-200	2.1	4
65	Validation of the CAMD Score in Patients With Chronic Hepatitis B Virus Infection Receiving Antiviral Therapy. *Clinical Gastroenterology and Hepatology*, **2020**, 18, 693-699.e1	6.9	16
64	Early detection of hepatocellular carcinoma in patients with diabetes mellitus. *European Journal of Gastroenterology and Hepatology*, **2020**, 32, 877-881	2.2	3
63	Radiologic Nonalcoholic Fatty Liver Disease Increases the Risk of Hepatocellular Carcinoma in Patients With Suppressed Chronic Hepatitis B. *Journal of Clinical Gastroenterology*, **2020**, 54, 633-641	3	10
62	Gender Matters: Characteristics of Hepatocellular Carcinoma in Women From a Large, Multicenter Study in the United States. *American Journal of Gastroenterology*, **2020**, 115, 1486-1495	0.7	16
61	Lifestyle and Environmental Approaches for the Primary Prevention of Hepatocellular Carcinoma. *Clinics in Liver Disease*, **2020**, 24, 549-576	4.6	4
60	Incidence of HCC recurrence after DAA treatment for HCV in a multicentre Italian cohort study. *Liver Cancer International*, **2020**, 1, 12-24	0.8	1
59	Type 2 Diabetes: A Risk Factor for Hospital Readmissions and Mortality in Australian Patients With Cirrhosis. *Hepatology Communications*, **2020**, 4, 1279-1292	6	6
58	Patterns of Comorbidity in Hepatocellular Carcinoma: A Network Perspective. *International Journal of Environmental Research and Public Health*, **2020**, 17,	4.6	5
57	Improved survival after treatments of patients with nonalcoholic fatty liver disease associated hepatocellular carcinoma. *Scientific Reports*, **2020**, 10, 9902	4.9	8
56	Assessment of risk factors, and racial and ethnic differences in hepatocellular carcinoma. *JGH Open*, **2020**, 4, 351-359	1.8	11
55	Long-term liver cancer incidence and mortality trends in the Changning District of Shanghai, China. *Journal of Digestive Diseases*, **2020**, 21, 230-236	3.3	2
54	AGA Clinical Practice Update on Screening and Surveillance for Hepatocellular Carcinoma in Patients With Nonalcoholic Fatty Liver Disease: Expert Review. *Gastroenterology*, **2020**, 158, 1822-1830	13.3	94
53	Plant-Based and Animal-Based Low-Carbohydrate Diets and Risk of Hepatocellular Carcinoma Among US Men and Women. *Hepatology*, **2021**, 73, 175-185	11.2	7
52	Association of Diabetes Mellitus and Cholangiocarcinoma: Update of Evidence and the Effects of Antidiabetic Medication. *Canadian Journal of Diabetes*, **2021**, 45, 282-290	2.1	2
51	Risk factors for the development of hepatocellular carcinoma (HCC) in chronic hepatitis B virus (HBV) infection: a systematic review and meta-analysis. *Journal of Viral Hepatitis*, **2021**, 28, 493-507	3.4	12

50	Association of Inflammatory and Insulinemic Potential of Diet and Lifestyle with Risk of Hepatocellular Carcinoma. *Cancer Epidemiology Biomarkers and Prevention*, **2021**, 30, 789-796	4	5
49	Effects of Positive Hepatitis B Core Antibody and Metabolic Disorders in Hepatocellular Carcinoma in an Endemic Area of Hepatitis B Virus. *Cancer Control*, **2021**, 28, 10732748211039758	2.2	
48	A global overview of genetically interpretable comorbidities among common diseases in UK Biobank.		1
47	Research Status and Prospect of Metabolic Abnormalities in Hepatocellular Carcinoma. *Advances in Clinical Medicine*, **2021**, 11, 2724-2729	0	
46	Diabetes mellitus und Fettlebererkrankungen. *Gastroenterologe*, **2021**, 16, 109-119	0.1	
45	Mechanisms Underlying Hepatocellular Carcinoma Progression in Patients with Type 2 Diabetes. *Journal of Hepatocellular Carcinoma*, **2021**, 8, 45-55	5.3	6
44	High Rates of Liver Cirrhosis and Hepatocellular Carcinoma in Chronic Hepatitis B Patients with Metabolic and Cardiovascular Comorbidities. *Microorganisms*, **2021**, 9,	4.9	1
43	NAFLD and MAFLD as emerging causes of HCC: A populational study. *JHEP Reports*, **2021**, 3, 100231	10.3	20
42	Identification of metabolism genes related to hepatocarcinogenesis and progression in type 2 diabetes mellitus via co-expression networks analysis. *Hereditas*, **2021**, 158, 14	2.4	0
41	Clinical impact of sexual dimorphism in non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). *Liver International*, **2021**, 41, 1713-1733	7.9	13
40	Distinctive features of hepatocellular carcinoma in non-alcoholic fatty liver disease. *Digestive and Liver Disease*, **2021**,	3.3	3
39	KASL clinical practice guidelines: Management of nonalcoholic fatty liver disease. *Clinical and Molecular Hepatology*, **2021**, 27, 363-401	6.9	21
38	Glucose-Like Peptide-1 Receptor Agonists and Hepatic Decompensation Events in Patients With Cirrhosis and Diabetes. *Clinical Gastroenterology and Hepatology*, **2021**,	6.9	2
37	Adiposity, Adulthood Weight Change, and Risk of Incident Hepatocellular Carcinoma. *Cancer Prevention Research*, **2021**, 14, 945-954	3.2	0
36	A global overview of genetically interpretable multimorbidities among common diseases in the UK Biobank. *Genome Medicine*, **2021**, 13, 110	14.4	6
35	Thiazolidinediones, alpha-glucosidase inhibitors, meglitinides, sulfonylureas, and hepatocellular carcinoma risk: A meta-analysis. *Metabolism: Clinical and Experimental*, **2021**, 120, 154780	12.7	1
34	Cancer Risk in Patients With Biopsy-Confirmed Nonalcoholic Fatty Liver Disease: A Population-Based Cohort Study. *Hepatology*, **2021**, 74, 2410-2423	11.2	23
33	Epidemiology and risk-stratification of NAFLD-associated HCC. *Journal of Hepatology*, **2021**, 75, 1476-1484	13.4	22

32	Anticancer Effect of Statins in Patients Undergoing Liver Transplantation for Hepatocellular Carcinoma. *Liver Transplantation*, **2021**,	4.5	1
31	[Type-2-diabetes and cancer risk]. *Deutsche Medizinische Wochenschrift*, **2021**, 146, 1218-1225	0	1
30	Effect of Nonalcoholic Fatty Liver Disease and Metabolic Risk Factors on Waitlist Outcomes in Patients With Hepatocellular Carcinoma. *Transplantation Direct*, **2020**, 6, e605	2.3	1
29	Gender differences in hepatocellular cancer: disparities in nonalcoholic fatty liver disease/steatohepatitis and liver transplantation. *Hepatoma Research*, **2018**, 4,	4.3	48
28	Emerging risk factors for nonalcoholic fatty liver disease associated hepatocellular carcinoma. *Hepatoma Research*, **2020**, 6,	4.3	5
27	The Role of Hepatitis C virus and Possible Risk factors in development of Hepatocellular carcinoma: 400 Patients based study. *The Egyptian Journal of Internal Medicine*, **2019**, 31, 64-72	0.5	3
26	Diabetes mellitus Typ 2 und Krebserkrankungen. *Diabetologe*, **2022**, 18, 18	0.2	
25	Metabolic syndrome and its component traits present gender-specific association with liver cancer risk: a prospective cohort study. *BMC Cancer*, **2021**, 21, 1084	4.8	0
24	Risk factors for the development of hepatocellular carcinoma (HCC) in chronic hepatitis B virus (HBV) infection: a systematic review and meta-analysis.		
23	Empagliflozin adjunct with metformin for the inhibition of hepatocellular carcinoma progression: Emerging approach for new application. *Biomedicine and Pharmacotherapy*, **2021**, 145, 112455	7.5	2
22	Changes in general and central fatness are associated with hepatocellular carcinoma: A Korean nationwide longitudinal study.. *International Journal of Cancer*, **2021**,	7.5	
21	Risk of liver-related events by age and diabetes duration in diabetic patients with non-alcoholic fatty liver disease.. *Hepatology*, **2022**,	11.2	3
20	Hepatocellular Carcinoma and Obesity, Type 2 Diabetes Mellitus, Cardiovascular Disease: Causing Factors, Molecular Links, and Treatment Options.. *Frontiers in Endocrinology*, **2021**, 12, 808526	5.7	4
19	The Importance of Metabolic Syndrome Status for the Risk of Non-Viral Hepatocellular Carcinoma: A Nationwide Population-Based Study. *Frontiers in Oncology*, **2022**, 12,	5.3	
18	Krebsrisiko bei Prdiabetes und Typ-2-Diabetes mellitus. *Diabetologie Und Stoffwechsel*,	0.7	
17	Typ-2-Diabetes mellitus und gastrointestinale Krebsvorsorge. *Zeitschrift Fur Gastroenterologie*,	1.6	
16	Mastering core recommendations during HEPAtology ROUNDS in advanced chronic liver disease. *Seminars in Liver Disease*,	7.3	
15	Development and prognosis of hepatocellular carcinoma in patients with diabetes.		0

14	Metabolisches Syndrom und Krebsrisiko. **2022**, 147, 1068-1077	
13	Interplay between fatty acids, SCD, mTORC1 and YAP/TAZ in promoting hepatocellular carcinoma. **2022**,	
12	Disruption of Growth Hormone Receptor Signaling Abrogates Hepatocellular Carcinoma Development. Volume 9, 823-837	1
11	Splenic artery ligation ameliorates postoperation liver function in HCC who underwent hepatectomy.	
10	Impact of diabetes, obesity, and dyslipidemia on the risk of HCC in patients with chronic liver diseases.	1
9	Typ-2-Diabetes mellitus und gastrointestinale Krebsvorsorge. **2022**, 20, 287-293	0
8	Higher Risk of Tumor Recurrence in NASH-Related Hepatocellular Carcinoma Following Curative Resection. **2022**, 14, 2427	0
7	Metabolisches Syndrom und gastrointestinale Krebsvorsorge.	0
6	Small Hepatitis B Virus Surface Antigen Promotes Hepatic Gluconeogenesis via Enhancing Glucagon/cAMP/Protein Kinase A/CREB Signaling.	0
5	In vivo assessment of the pharmacokinetic interactions between donafenib and dapagliflozin, donafenib and canagliflozin in rats. **2023**, 162, 114663	0
4	Impact of metformin on the incidence of human cholangiocarcinoma in diabetic patients: a systematic review and meta-analysis. **2023**, 35, 241-247	0
3	Non-alcoholic Fatty Liver Disease (NAFLD), Type 2 Diabetes, and Non-viral Hepatocarcinoma: Pathophysiological Mechanisms and New Therapeutic Strategies. **2023**, 11, 468	3
2	Adapted Diabetes Complications Severity Index and Charlson Comorbidity Index in predicting all-cause and cause-specific mortality among patients with type 2 diabetes. **2023**, 11, e003262	0
1	Pathogenesis of Hepatocellular Carcinoma: The Interplay of Apoptosis and Autophagy. **2023**, 11, 1166	0